Immune response and one-year antibody persistence after a fourth dose of a novel haemophilus influenzae type b and neisseria meningitidis serogroups c and y-tetanus toxoid conjugate vaccine (hibmency) at 12 to 15 months of age

Pediatric Infectious Disease Journal

Volumn 29, Issue 5, 2010, Pages 469-471

  Marshall, Gary S ^a   Marchant, Colin D ^b   Blatter, Mark ^c   Aris, Emmanuel ^d,e   Boutriau, Dominique ^d,e   Poolman, Jan T ^d,e   Friedland, Leonard R ^d,e   Miller, Jacqueline M ^d,e  

^a University of Louisville School of Medicine   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c Primary Physicians Research   (United States)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Booster; Haemophilus influenzae type b; Meningitis; Neisseria meningitidis serogroup C; Neisseria meningitidis serogroup Y; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HIBMENCY; PNEUMOCOCCUS VACCINE; PRION PROTEIN ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY DETECTION; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CHILD; DROWSINESS; DRUG FATALITY; DRUG SAFETY; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; IRRITABILITY; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT;

ANTIBODIES, BACTERIAL; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; LONGITUDINAL STUDIES; MICROBIAL VIABILITY; TETANUS TOXOID; TIME FACTORS; VACCINATION; VACCINES, CONJUGATE;

EID: 77951819120     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181cdd379     Document Type: Article

References (10)

1. Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2010;29:48-52.
2. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol. 1997;4:156-157.
3. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129: 1307-1326.
4. Käyhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100. (Pubitemid 13068358)
5. Nolan T, Lambert S, Roberton D, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when coadministered with DTaP-HepB-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25:8487-8499.
6. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningo-coccal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367.
7. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745-1752.
8. Larrauri A, Cano R, García M, et al. Impact and effectiveness of menin-gococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097-4100.
9. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. Available at: http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm. Accessed September 19 2008.
10. Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2004;23:429-435.